ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced the launch of Cholestyramine for Oral Suspension USP, 4g/dose, in cans. The current annual U.S. market for this product is approximately $22 million, according to Iqvia/IMS Health.
Arthur S. Przybyl, ANI’s President and CEO stated, “This launch is the tenth product that ANI has successfully completed a manufacturing site transfer and recommercialized. These product launches are from previously discontinued ANDA’s that ANI has acquired over the last several years. We continue to commit product development resources in order to launch additional discontinued ANDA’s that we believe can provide us with meaningful cash flow once re-commercialized.”
About Cholestyramine for Oral Suspension USP
Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet.
Cholestyramine for Oral Suspension USP may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern.
Cholestyramine for Oral Suspension USP monotherapy has been demonstrated to retard the rate of progression and increase the rate of regression of coronary atherosclerosis.
Cholestyramine for Oral Suspension USP is also indicated for the relief of pruritus associated with partial biliary obstruction.